Human Genome Sciences Inc. got a double dose of bad news last week as partner Novartis AG withdrew its European marketing application for hepatitis C drug Zalbin (albinterferon alfa-2b) and lupus drug Benlysta (belimumab) turned up mixed results in a long-term analysis from a Phase III trial. Read More
